AI Article Synopsis
- Researchers are exploring a novel cell transplantation method using reprogrammed peripheral blood mononuclear cells (PBMCs) turned into induced mesenchymal stem cells (iMSCs) for treating chronic renal insufficiency.
- An animal model of chronic renal insufficiency, created through unilateral ureteral obstruction, was used to evaluate the effectiveness of these iMSCs compared to non-induced PBMCs.
- The study aims to assess the therapeutic potential of iMSC transplantation in managing chronic renal issues, hoping to provide new treatment options.
Article Abstract
Discovering a new cell transplantation approach for treating chronic renal insufficiency is a goal of many nephrologists. In vitro-cultured peripheral blood mononuclear cells (PBMCs) were reprogrammed into induced mesenchymal stem cells (iMSCs) by using natural inducing agents made in our laboratory. The stem cell phenotype of the iMSCs was then identified. Unilateral ureteral obstruction (UUO) was used to create an animal model of chronic renal insufficiency characterized by renal interstitial fibrosis. The induced and non-induced PBMCs were transplanted, and the efficacy of iMSCs in treating chronic renal insufficiency was evaluated using a variety of methods. The ultimate goal was to explore the effects of iMSC transplantation on the treatment of chronic renal insufficiency, with the aim of providing a new therapeutic modality for this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5405955 | PMC |
| http://journals.plos.org/plosone/article?id=10.1371/journal.pone.0176273 | PLOS |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!